Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade

被引:10
|
作者
Rowe, Jared H. [1 ,2 ,3 ]
Elia, Ilaria [4 ,5 ]
Shahid, Osmaan [2 ,3 ]
Gaudiano, Emily F. [2 ,3 ]
Sifnugel, Natalia E. [2 ,3 ]
Johnson, Sheila [4 ]
Reynolds, Amy G. [1 ]
Fung, Megan E. [2 ,3 ]
Joshi, Shakchhi [4 ]
LaFleur, Martin W. [2 ,3 ]
Park, Joon Seok [2 ,3 ]
Pauken, Kristen E. [2 ,3 ]
Rabinowitz, Joshua D. [6 ]
Freeman, Gordon J. [7 ]
Haigis, Marcia C. [4 ]
Sharpe, Arlene H. [2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA
[2] Blavatnik Inst, Harvard Med Sch, Dept Immunol, Boston, MA USA
[3] Lay Inst Immunol & Inflammat, Harvard Med Sch & Brigham & Womens Hosp, Boston, MA USA
[4] Blavatnik Inst, Harvard Med Sch, Dept Cell Biol, Boston, MA USA
[5] Dept Cellular & Mol Med, Leuven, Belgium
[6] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ USA
[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
ONE-CARBON METABOLISM; TUMOR MICROENVIRONMENT; SACCHAROMYCES-CEREVISIAE; NIVOLUMAB; SERINE; ACTIVATION; IPILIMUMAB;
D O I
10.1158/2159-8290.CD-22-1301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metabolic support, in the form of formate supplementation, combined with anti-PD-1 improves antitumor CD8+ T-cell fitness and tumor control, revealing a strategy that can be used to extend the benefits of anti-PD-1 therapy. Abstract The tumor microenvironment (TME) restricts antitumor CD8(+) T-cell function and immunotherapy responses. Cancer cells compromise the metabolic fitness of CD8(+) T cells within the TME, but the mechanisms are largely unknown. Here we demonstrate that one-carbon (1C) metabolism is enhanced in T cells in an antigen-specific manner. Therapeutic supplementation of 1C metabolism using formate enhances CD8(+) T-cell fitness and antitumor efficacy of PD-1 blockade in B16-OVA tumors. Formate supplementation drives transcriptional alterations in CD8(+) T-cell metabolism and increases gene signatures for cellular proliferation and activation. Combined formate and anti-PD-1 therapy increases tumor-infiltrating CD8(+) T cells, which are essential for enhanced tumor control. Our data demonstrate that formate provides metabolic support to CD8(+) T cells reinvigorated by anti-PD-1 to overcome a metabolic vulnerability in 1C metabolism in the TME to further improve T-cell function. Significance: This study identifies that deficiencies in 1C metabolism limit the efficacy of PD-1 blockade in B16-OVA tumors. Supplementing 1C metabolism with formate during anti-PD-1 therapy enhances CD8(+) T-cell fitness in the TME and CD8(+) T-cell-mediated tumor clearance. These findings demonstrate that formate supplementation can enhance exhausted CD8(+) T-cell function. See related commentary by Lin et al., p. 2507. This article is featured in Selected Articles from This Issue, p. 2489
引用
收藏
页码:2566 / 2583
页数:18
相关论文
共 50 条
  • [41] Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay
    Gallotta, Marilena
    Assi, Hikmat
    Degagne, Emilie
    Kannan, Shravan Kumar
    Coffman, Robert L.
    Guiducci, Cristiana
    CANCER RESEARCH, 2018, 78 (17) : 4943 - 4956
  • [42] PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
    Peng, Weiyi
    Liu, Chengwen
    Xu, Chunyu
    Lou, Yanyan
    Chen, Jieqing
    Yang, Yan
    Yagita, Hideo
    Overwijk, Willem W.
    Lizee, Gregory
    Radvanyi, Laszlo
    Hwu, Patrick
    CANCER RESEARCH, 2012, 72 (20) : 5209 - 5218
  • [43] NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells
    Raffo Iraolagoitia, Ximena L.
    Spallanzani, Raul G.
    Torres, Nicolas I.
    Araya, Romina E.
    Ziblat, Andrea
    Domaica, Carolina I.
    Sierra, Jessica M.
    Nunez, Sol Y.
    Secchiari, Florencia
    Gajewski, Thomas F.
    Zwirner, Norberto W.
    Fuertes, Mercedes B.
    JOURNAL OF IMMUNOLOGY, 2016, 197 (03): : 953 - 961
  • [44] Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+T cells against HNSCC cells in vitro
    Wang, Xiangjian
    Xu, Shenjie
    Fu, Tao
    Wu, Yang
    Sun, Weilian
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2023, 52 (09) : 834 - 842
  • [45] Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer
    O'Malley, Grace
    Treacy, Oliver
    Lynch, Kevin
    Naicker, Serika D.
    Leonard, Niamh A.
    Lohan, Paul
    Dunne, Philip D.
    Ritter, Thomas
    Egan, Laurence J.
    Ryan, Aideen E.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (11) : 1426 - 1441
  • [46] PD-1 expression is markedly upregulated on intratumoral CD4+ and CD8+ T cells in follicular lymphoma and is associated with T-Cell exhaustion
    Nattamai, Durgha
    Neelapu, Sattva S.
    BLOOD, 2007, 110 (11) : 808A - 808A
  • [47] CD40L+ CD8+ T-Cell Dependent Antitumor Immunity
    Thiel, Andreas
    Frentsch, Marco
    Listopad, Joanna
    Stark, Regina
    Japp, Alberto Sada
    Matzmohr, Nadine
    Meier, Sarah
    Taniuchi, Ichiro
    Blankenstein, Thomas
    BLOOD, 2014, 124 (21)
  • [48] Rewiring CD8+ T cell responses to PD-1 immune checkpoint blockade in PDAC via the inhibitory receptor PSGL-1
    Hope, Jennifer L.
    Zhang, Yijuan
    Hetrick, Hannah A. F.
    Hernandez, Evelyn S. Sanchez
    Romano, Gabriele
    Roy, Sreeja
    Lin, Michelle
    Palete, Ashley B.
    Maganti, Swetha
    Otero, Dennis C.
    Byrne, Katelyn T.
    Commisso, Cosimo
    Bradley, Linda M.
    CANCER RESEARCH, 2024, 84 (17)
  • [49] Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
    Chang, Chien-Hsing
    Wang, Yang
    Li, Rongxiu
    Rossi, Diane L.
    Liu, Donglin
    Rossi, Edmund A.
    Cardillo, Thomas M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77 (19) : 5384 - 5394
  • [50] Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer
    Luo, Jie
    Cheng, Kebin
    Ji, Xianxiu
    Gao, Caixia
    Zhu, Ren
    Chen, Jiayi
    Xue, Wenjun
    Huang, Qi
    Xu, Qingqiang
    CANCER LETTERS, 2024, 591